{
    "nctId": "NCT05244993",
    "briefTitle": "AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer",
    "officialTitle": "AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Neoplasm Female",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 42,
    "primaryOutcomeMeasure": "Overall Response Rate (ORR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female aged 18-75 years old.\n* ECOG 0 or 1 point.\n* Advanced triple-negative invasive breast cancer :\n\n  1. The pathological classification is triple negative, specifically:\n\n     1. ER negative: IHC\\<1%.\n     2. PR negative: IHC\\<1%.\n     3. HER2 negative: IHC-/+ or IHC++ but FISH/CISH is negative.\n  2. Tumor staging: locally advanced or recurrent/metastatic breast cancer.\n* If the last chemotherapy drug in the previous adjuvant/neoadjuvant treatment stage is paclitaxel, paclitaxel liposome, paclitaxel albumin or docetaxel, it will take \u22656 months from the end of treatment to enrollment.\n* At least one objectively measurable lesion according to the RECIST 1.1 .\n* The main organs are functioning well, and the blood test results within 14 days before enrollment should meet the following requirements:\n\n  1. Routine blood test:\n\n     1. Hemoglobin (HB) \u226590 g/L.\n     2. Neutrophil count (ANC) \u22651.5\u00d7109/L.\n     3. Platelet count (PLT) \u2265100\u00d7109/L.\n  2. Biochemical test:\n\n     1. Total bilirubin\u22641.5\u00d7ULN (upper limit of normal).\n     2. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u2264 2.5\u00d7ULN; if there is liver metastasis, ALT and AST \u2264 5\u00d7ULN.\n     3. Serum creatinine (Cr) \u22641.5 ULN or creatinine clearance \u226560mL/min.\n* Must not be regnant.\n* Volunteer to participate in this study and sign an informed consent form.\n\nExclusion Criteria:\n\n* Pregnant, lactating or planning to become pregnant during the study period.\n* Allergic to any of the drugs in the study.\n* Previously received PD-1/PD-L1 antibody, CTLA-4 antibody, or anti-vascular targeted therapy.\n* Central nervous system (CNS) metastases.\n* Concomitant disease/medical history:\n\n  1. Patients with any known or suspected autoimmune diseases.\n  2. Hypertension.\n  3. Peripheral neuropathy \u2265 Grade 2.\n  4. Persons with a history of unstable angina or arrhythmia.\n  5. Active or uncontrolled serious infection .\n  6. History of immunodeficiency.\n  7. Active hepatitis B or C.\n  8. interstitial lung disease or non-infectious pneumonia.\n  9. Active tuberculosis.\n  10. Urine protein is \u2265++, and 24-hour urine protein quantitative is \\>1.0g.\n  11. Suffered from other malignant tumors within 5 years before enrollment.\n  12. Unreduced toxicity .\n  13. Multiple factors that affect oral medications.\n  14. Abnormal coagulation function.\n  15. Major surgical treatment, open biopsy or traumatic injury within 4 weeks.\n  16. Tumor has invaded the periphery of important blood vessels.\n  17. Patients who have seizures.\n  18. Bleeding constitution or medical history.\n  19. Arterial/venous thrombotic events before enrollment or within 6 months.\n  20. Live attenuated vaccine vaccination within 28 days before the study.\n  21. Uncontrollable pleural, abdominal or pericardial effusion.\n  22. Other uncontrollable systemic diseases.\n* Other serious physical or mental diseases or laboratory abnormalities.\n* Patients who the researcher thinks are not suitable for this research.\n* Participated in clinical trials of other anti-tumor drugs within four weeks.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}